Anuj Maheshwari

Dr. Anuj Maheshwari

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 June 2025 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Open access
AZAbdul Hamid Zargar
Abdul Hamid Zargar
ABAnil Bhansali
Anil Bhansali
AMAnirban Majumdar
Anirban Majumdar
AMAnuj Maheshwari
Anuj Maheshwari
ABArpandev Bhattacharyya
Arpandev Bhattacharyya
VMViswanathan Mohan
Viswanathan Mohan
In India, the increasing prevalence of diabetes and obesity poses a significant threat towards a surge in the incidence of metabolic dysfunction‐associated steatotic liver disease (MASLD), formerly known as non‐alcoholic fatty liver disease (NAFLD). Concomitant with the evolving guidelines, there is a need to direct and spread awareness among practicing diabetologists to identify and screen high‐risk individuals for MASLD for timely management. Its asymptomatic nature and the evolving guidelines on diagnosis have hindered the precise estimates of MASLD in the high‐risk group of individuals in a clinical setting. Therefore, an expert panel of diabetologists from India convened to review, discuss and document the approach towards screening, diagnosis and management of MASLD. Serum biomarkers, simple non‐invasive tools and imaging techniques could direct the risk stratification of the patients. Early lifestyle interventions including weight loss and exercise are beneficial. The pharmacological landscape of drugs directed to insulin resistance, lipid metabolism, oxidative stress, inflammation, apoptosis and fibrogenesis pathways for the management of MASLD is expanding. In summary, the consensus statements are expected to serve as a useful guide in the screening and management of MASLD in the region and to direct a well‐planned study design that could enhance the scientific value of these statements.

5 November 2019 in International Journal of Diabetes in Developing Countries
Verified
Journal Article
Closed access
PDF file
RCRajeev Chawla
Rajeev Chawla
BMB. M. Makkar
B. M. Makkar
SASudeepta Aggarwal
Sudeepta Aggarwal
SBSarita Bajaj
Sarita Bajaj
ADAshok Kumar Das
Ashok Kumar Das
AZAh Zargar
Ah Zargar

2 February 2026 in Diabetes Therapy
Verified
Journal Article
Open access
PDF file
JKJothydev Kesavadev
Jothydev Kesavadev
VMViswanathan Mohan
Viswanathan Mohan
SJShashank Joshi
Shashank Joshi
BSBanshi Saboo
Banshi Saboo
MCManoj Chawla
Manoj Chawla
AAAbin Augustine
Abin Augustine
Despite revolutionizing diabetes care globally, continuous glucose monitoring (CGM) adoption in India remains limited, as a result of several economic, infrastructural, clinical, and sociocultural concerns. This narrative review aims to map unmet needs and propose practical, context-specific solutions. Continuous use of CGM remains the preferred approach for optimal glucose management and achieving long-term metabolic advantages, providing insights for proactive, data-driven, and preventive diabetes care. However, main barriers to CGM uptake include limited awareness among people with diabetes and healthcare providers, high costs, lack of reimbursement, limited device availability beyond major cities, and economic, infrastructural, and sociocultural access inequities across urban and rural populations. The psychological burden from frequent alarms, data fatigue, and stigma with noticeable or intrusive devices add to these challenges. Addressing these barriers necessitates a multifaceted strategy involving affordable, climate-adapted devices, interoperable digital ecosystems, India-specific reimbursement models, and robust educational infrastructure. The emergence of cost-effective CGM devices with a range of advanced features, such as predictive glucose algorithms and personalized pattern identification, is pivotal to this effort. These innovations improve clinical outcomes and quality of life by simplifying the user experience, addressing challenges, such as alarm fatigue while translating complex data into actionable insights, facilitating widespread CGM adoption in India.

4 October 2024 in Journal of Human Hypertension
Verified
Journal Article
Closed access
PDF file
AMAnuj Maheshwari
Anuj Maheshwari
RGRajeev Gupta
Rajeev Gupta
NVNarsingh Verma
Narsingh Verma
SNS. N. Narasingan
S. N. Narasingan
RSRam B. Singh
Ram B. Singh
AMA. Muruganathan
A. Muruganathan

1 August 2020 in European Heart Journal Supplements
Verified
Journal Article
Open access
PDF file
AMAnuj Maheshwari
Anuj Maheshwari
NVNarsingh Verma
Narsingh Verma
SBShipra Bhardwaj
Shipra Bhardwaj
AJArun P Jose
Arun P Jose
SBSandeep Bhalla
Sandeep Bhalla
NPNeil R Poulter
Neil R Poulter
Hypertension (HTN) is the greatest attributable risk factor for cardiovascular disease in India. Recent studies have reported the crude prevalence of HTN in India to be 25.3%. In the May Measurement Month (MMM) screening campaign of 2017 conducted in India, 31.8% had HTN. In order to ratify earlier results, and further understand the awareness and control levels of HTN in India, organizations that participated in MMM 2017 decided to participate in the MMM global screening initiative of the International Society of Hypertension for a 2nd consecutive year. A total of 345 234 individuals were screened in MMM 2018. There were more than 1000 screening locations that included hospitals, clinics, workplaces, and special health camps organized across the country. After applying multiple imputation, a total of 111 462 (32.3%) individuals had HTN of whom 63 415 (55.6%) were aware of HTN and 61 646 (55.3%) were on antihypertensive medicines, out of which 15 583 (25.3%) were uncontrolled. Overall 57 864 (41.3%) hypertensives were uncontrolled. About half (44.7%) of hypertensive population in India were not on treatment. Around two-thirds (65.7%, n = 226 924) had not measured their blood pressure (BP) in last 12 months and 64% measured their BP for the first time in their life during the campaign, which strongly indicates the need for large scale awareness drives. This study suggests that opportunistic periodic public health screening at a national level is needed to increase HTN detection, treatment, control, and countrywide awareness in highly populated nations like India.

1 January 2025 in Journal of Diabetes, Metabolic Disorders & Control
Verified
Journal Article
Open access
PDF file
AMAnuj Maheshwari
Anuj Maheshwari
VVVijay Viswanathan
Vijay Viswanathan
SASanjay Agarwal
Sanjay Agarwal
AGAmit Kumar Gupta
Amit Kumar Gupta
NVNarsingh Verma
Narsingh Verma
NKNeelesh Kapoor
Neelesh Kapoor
Type 2 Diabetes Mellitus (T2DM) is a growing public health crisis globally, with rural India experiencing a significant increase in prevalence due to urbanization, lifestyle changes, and limited healthcare access. This review highlights the multifaceted challenges of T2DM management in rural India, including inadequate awareness, delayed diagnosis, and suboptimal treatment adherence. Factors such as genetic predisposition, socio-economic barriers, and cultural beliefs exacerbate the burden while resource constraints in rural healthcare systems hinder effective disease management. Innovations like mobile health technologies, government initiatives, and community-based education programs have shown promise in bridging healthcare gaps. This paper also emphasizes the critical role of structured diabetes education, affordable medication access, and culturally sensitive interventions in improving glycemic control and preventing complications. Strengthening primary healthcare infrastructure, fostering public-private partnerships, and integrating traditional and allopathic medicine are identified as essential strategies to address this pressing health issue. The findings call for comprehensive policies that prioritize early detection, lifestyle modifications, and equitable healthcare delivery to mitigate the rising diabetes burden in Indi’s underserved areas.